Medscape wonders how Lilly’s making tirzepatide available in vials will affect the GLP-1 market....
Quartz mentions APC
In a piece on the battle between Eli Lilly and compounding pharmacists over tirzepatide — notably the lawsuit by the Outsourcing Facilities Association — Quartz magazine referenced APC’s statement telling 503A members to “immediately cease preparing and dispensing compounded copies of Mounjaro and Zepbound.”